Epitalon structure and telomere studies

Epitalon, also written Epithalon, is the four-amino-acid peptide Ala: Glu: Asp: Gly. Laboratory papers report changes in telomerase-related measurements and telomere length in particular cell cultures. Those findings describe experimental observations, not proof that this peptide slows aging or extends lifespan in people. 1 2 3

What is the molecular structure of epitalon?

PubChem lists AEDG as the one-letter sequence and H: Ala: Glu: Asp: Gly: OH as the condensed structure. The terminal OH identifies the free carboxyl terminus in that reference form. The chain contains four residues; the sequence itself should not be confused with the quantity printed on a vial. 1

1

Are epitalon, epithalon and epithalamin the same thing?

Epitalon and Epithalon are naming variants for the tetrapeptide in the compound record. The original 2003 paper describes its design in relation to Epithalamine, a complex preparation obtained from animal pineal tissue. A defined synthetic four-residue peptide and a tissue-derived preparation are different materials. 1 3

This matters when reading older studies. A result attributed to a preparation containing multiple components cannot automatically be assigned to one defined molecule. The material name, composition and analytical identification need to match before evidence is carried across.

What do the telomerase studies actually show?

The 2003 report examined human fetal fibroblasts in culture and reported telomerase activity and telomere elongation after exposure to Epithalon. Human-derived cells are not a trial in human participants; the experimental setting is part of the finding. 3

A 2025 study examined normal epithelial and fibroblast cells alongside breast-cancer cell lines. It reported telomere-length changes associated with hTERT expression and telomerase activity in normal cells, while alternative lengthening of telomeres, or ALT, contributed in the cancer-cell experiments. The response therefore depended on the cell context. 2

These are downstream molecular measurements. They do not, on their own, establish a complete receptor-to-outcome pathway, a beneficial whole-body effect or a clinical safety profile. Cancer-cell findings also should not be rewritten as evidence that the peptide prevents or treats cancer.

Why should the chemical form be recorded?

FDA’s 2026 chemistry briefing lists the reference peptide and an acetate form separately. Its table gives 390.35 g/mol for the peptide and 450.40 g/mol for the listed one-acetate composition. A reference molecular weight therefore needs a chemical-form label, rather than being copied onto every preparation. 4

The counterion does not add another amino acid to AEDG. It changes the chemical composition being described and can affect how a weighed sample is interpreted. A vial’s nominal mass, chromatographic purity and actual peptide content remain different measurements.

What is a fair conclusion from this evidence?

The structure can be stated precisely, while the biological conclusion stays limited to what was measured. A telomere-length result is not the same outcome as longer healthy survival, improved function or reduced disease in a clinical population. Those claims would require evidence designed to test them.

For a useful research record, document the exact peptide and form, experimental cell type, measured endpoint and source date. This preserves the difference between a molecular observation, a proposed explanation and a demonstrated clinical benefit.

EPS documentation

Use the research catalogue to check the exact name, labelled amount and format. The COA library publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch.